External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Haematology Follicular Lymphoma

Follicular Lymphoma

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Dec 13 / Roche and Genentech
Mosunetuzumab▼ is cost-effective compared with alternative novel treatment options in patients with third-line or later relapsed/refractory follicular lymphoma over a long-term horizon in the United States
A cost-effectiveness analysis was conducted, using a simulated partitioned survival model with health states of progression-free survival, post-progression survival, and death, to compare mosunetuzumab▼ with alternative treatment options. The cost-effectiveness of these therapies from a United States payer perspective are presented.
Haematology Oncology Follicular Lymphoma ASH-2024

Sign up or login to unlock the full suite of MEDICALLY features
Dec 13 / Roche and Genentech
Lower total cost of care with mosunetuzumab▼ compared with alternative novel treatment options in third-line or later relapsed/refractory follicular lymphoma: a United States third-party payer perspective
A micro-economic analysis was conducted to evaluate the total cost of care of mosunetuzumab▼ compared with alternative novel treatment options in patients with third-line or later relapsed/refractory follicular lymphoma. Comparisons of the total cost of care of these therapies from a United States third-party payer perspective are presented.
Haematology Oncology Follicular Lymphoma ASH-2024

Sign up or login to unlock the full suite of MEDICALLY features
Dec 9 / Roche and Genentech
Mosunetuzumab▼ continues to demonstrate clinically meaningful outcomes in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies including those with a history of POD24: 4-year follow-up of a pivotal Phase II study
GO29781 is a Phase II study of mosunetuzumab▼ in patients with relapsed/refractory follicular lymphoma after ≥2 prior lines of therapy. Updated efficacy and safety data after 4 years of follow up are presented.
Haematology Oncology Follicular Lymphoma ASH-2024

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.